Combating Alzheimer's Through Sleep and Exercise

Inclusion criteria

• Aged 55-80 years at the time of the screening visit
• Able to ambulate safely and independently
• Able to safely perform moderate-intensity exercise as per the Physical Activity Readiness Questionnaire (PAR-Q, a validated exercise readiness questionnaire)
• Able to wear and use Fitbit wristwatch and/or the Elemind Neuromodulation headband and Lys devices
• Able to operate a digital device like mobile phone or computer
• Able and willing to provide venous blood samples
• Able to understand and speak English (our AR-based MCI diagnosis tool does not yet have capacity for other languages)
• Able to self-report a history of cognitive changes or impairment
• Be cognitively able (including those with and without MCI) and willing to provide informed consent
• Body weight <400 pounds (<181.4kg) in order to safely operate the NuStep T4r Recumbent Stepper stationary bicycle

Exclusion criteria

• Severe mobility limitations that prevent safe participation in moderate exercise protocols
• Unstable or uncontrolled medical conditions (e.g., recent cardiovascular event (<6 months), cerebrovascular accident or transient ischemic attack (<6 months), active cancer, or uncontrolled diabetes) that pose safety concerns
• Inability to complete intake screening procedures
• Severe uncorrected hearing impairment-particularly if it precludes effective utilization of the Elemind Neuromodulation headband-and/or vision impairment that interferes with digital device usage or in-person exercise guidance
• Determined to have Alzheimer's/dementia based on performance on the Quick Mild Cognitive Impairment (QMCI).
• Inability or unwillingness to learn or engage with digital devices (e.g., smartphone, Fitbit, Elemind, or Lys), even with staff support
• Regular pre-study engagement in ≥150 minutes of moderate-level and/or ≥75 minutes of vigorous-level exercise per week based on Fitbit data obtained during the initial seven-day onboarding screening period
• Determined to have sufficient sleep, as defined by a sleep efficiency mean of ≥80%) based on Elemind Neuromodulation headband data obtained during the initial seven-day onboarding screening period
• Current usage of disease-modifying therapy targeting amyloid (e.g., anti-amyloid monoclonal antibodies) or tau
• Body weight ≥400 pounds (≥181.4kg), which would pose a safety risk during the operation of the NuStep recumbent stationary bicycle